Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891735 · ClinicalTrials.gov registry record · Phase 3
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,097
- Enrollment target
NCT00891735 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 1,097 participants.
The verdict
NCT00891735, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,097 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,097 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891735
The ClinicalTrials.gov registry entry for NCT00891735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,097 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00891735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00891735 about?
NCT00891735 is a clinical study titled "A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)". This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the fi...
What is the current status of trial NCT00891735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,097 participants. The study started on 2009-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00891735?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00891735?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.